Adlon Therapeutics
Manufacturing · Connecticut, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
201 Tresser Blvd, Stamford, Connecticut,...Phone Number
(888) 827-0618Website
www.adlontherapeutics.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Adlon Therapeutics
Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P., is a specialty pharmaceutical company committed to providing treatment options for patients who suffer from the symptoms of Attention Deficit/Hyperactivity Disorder (ADHD). Our mission is to serve patients and the ADHD community by developing innovative medicines and supporting responsible prescription stimulant utilization through awareness, research, and supporting policies that align with the appropriate diagnosis and treatment of ADHD.Explore more
Adlon Therapeutics Org Chart
MO
Specialty Sales Representative
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Adlon Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Adlon Therapeutics
Check out if Adlon Therapeutics is spiking on competitors!
Adlon Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Click to see if Adlon Therapeutics had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Adlon Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Adlon Therapeutics recently announced quarterly report
Check if Adlon Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Adlon Therapeutics launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Adlon Therapeutics
Compare insights from companies similar to Adlon Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Adlon Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Adlon Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Adlon Therapeutics.
Adlon Therapeutics Tech Stack
A closer look at the technologies used by Adlon Therapeutics
Adlon Therapeutics News & Media
Adlon Therapeutics L.P. Announces Publication of Data from Adhansia XR® (methylphenidate HCl) Extended-Release Capsules CII Studies Examining Sleep Quality Outcomes in CNS Drugs
STAMFORD, Conn.--(BUSINESS WIRE)--Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P., today announced the publication of post-hoc analyses of data from a randomized, double‑blind, forced‑dose, placebo‑controlled safety and efficacy study and a six‑month open‑label safety extension study of Adhansia XR® (methylphenidate hydrochloride) extended-release capsules CII in the journal CNS Drugs. The studies evaluated the effect of Adhansia XR on sleep in adults with Attention-Deficit/HyperactAdlon Therapeutics L.P. Announces Two New Publications of Adhansia XR® (methylphenidate HCl) Extended-Release Capsules CII Data
STAMFORD, Conn.--(BUSINESS WIRE)--Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P., announced two recent online publications of studies related to the efficacy, safety and pharmacokinetics of Adhansia XR® (methylphenidate hydrochloride) extended-release capsules CII (investigationally known as PRC-063). Research published in the Journal of Child and Adolescent Psychopharmacology examined the efficacy and safety of Adhansia XR in children 6 to 12 years of age with Attention-Deficit/HyAdlon Therapeutics L.P. and the Prescription Drug Safety Network Launch New Resources to Encourage Safe and Responsible Use of Prescription Stimulant Medications
STAMFORD, Conn.--(BUSINESS WIRE)--Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P., and the Prescription Drug Safety Network (“the Network”) today announced the availability of a new interactive video series and digital course for those diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD) and their parents and caregivers. The Network is a nationwide coalition of public and private-sector organizations convened by EVERFI, a national leader in prevention education, to help adAdlon Therapeutics L.P. and Purdue Pharma L.P. Will Present Data from Adhansia XR™ (methylphenidate HCl) Studies Examining Sleep Quality Outcomes, Functional Outcomes and Executive Functioning at the 2020 APSARD Annual Meeting
STAMFORD, Conn.--(BUSINESS WIRE)--Adlon Therapeutics L.P. and Purdue Pharma L.P. will present data from three studies evaluating PRC-063 at the 2020 American Professional Society of ADHD and Related Disorders (APSARD) Annual Meeting in Washington D.C. PRC-063 was approved by the U.S. Food and Drug Administration (FDA) for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in patients six years and older and is currently available as Adhansia XR™ (methylphenidate hydrochloride) ext
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Adlon Therapeutics
Sign Up For FreeTo access detailed company insights
Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P., is a specialty pharmaceutical company committed to providing treatment options for patients who suffer from the symptoms of Attention Deficit/Hyperactivity Disorder (ADHD). Our mission is to serve patients and the ADHD community by developing innovative medicines and supporting responsibl... Read More
